PHAXIAM Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di PHAXIAM Therapeutics diminuiranno del 2.2% all'anno, mentre si prevede che il fatturato annuo crescerà del 82.8% all'anno. Si prevede che l'EPS crescerà del 67.3% all'anno.

Informazioni chiave

-3.5%

Tasso di crescita degli utili

-1.7%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	34.9%
Tasso di crescita dei ricavi	92.4%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	10 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

LSE:0QSS - Stime future degli analisti e dati finanziari passati (EUR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	13	-19	-39	N/A	2
12/31/2025	2	-32	-33	N/A	2
12/31/2024	1	-25	-29	N/A	2
6/30/2024	2	-22	N/A	N/A	N/A
3/31/2024	2	-23	N/A	N/A	N/A
12/31/2023	1	-23	-25	-24	N/A
9/30/2023	6	-12	N/A	N/A	N/A
6/30/2023	6	-11	-23	-23	N/A
3/31/2023	6	6	N/A	N/A	N/A
12/31/2022	7	0	-32	-32	N/A
9/30/2022	2	-18	N/A	N/A	N/A
6/30/2022	3	-27	-45	-45	N/A
3/31/2022	3	-54	N/A	N/A	N/A
12/31/2021	4	-54	-57	-57	N/A
9/30/2021	4	-61	N/A	N/A	N/A
6/30/2021	4	-66	-55	-55	N/A
3/31/2021	4	-68	N/A	N/A	N/A
12/31/2020	4	-73	-53	-52	N/A
9/30/2020	4	-73	N/A	N/A	N/A
6/30/2020	4	-68	-52	-49	N/A
3/31/2020	5	-69	N/A	N/A	N/A
12/31/2019	5	-63	-63	-43	N/A
9/30/2019	6	-52	-69	-38	N/A
6/30/2019	5	-49	-73	-52	N/A
3/31/2019	4	-38	N/A	N/A	N/A
12/31/2018	4	-38	-53	-48	N/A
9/30/2018	3	-42	N/A	N/A	N/A
6/30/2018	4	-38	-33	-31	N/A
3/31/2018	3	-39	N/A	N/A	N/A
12/31/2017	3	-34	N/A	-25	N/A
9/30/2017	4	-27	N/A	N/A	N/A
6/30/2017	4	-26	N/A	-23	N/A
3/31/2017	5	-24	N/A	N/A	N/A
12/31/2016	4	-22	N/A	-18	N/A
9/30/2016	4	-20	N/A	-17	N/A
6/30/2016	4	-19	N/A	-17	N/A
3/31/2016	3	-16	N/A	N/A	N/A
12/31/2015	3	-15	N/A	-15	N/A
9/30/2015	3	-14	N/A	-12	N/A
6/30/2015	2	-12	N/A	-10	N/A
3/31/2015	2	-11	N/A	-9	N/A
12/31/2014	2	-9	N/A	-7	N/A
9/30/2014	2	-8	N/A	-7	N/A
6/30/2014	2	-7	N/A	-6	N/A
3/31/2014	2	-8	N/A	-6	N/A
12/31/2013	2	-8	N/A	-6	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 0QSS rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 0QSS rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 0QSS rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 0QSS ( 82.8% all'anno) crescerà più rapidamente del mercato UK ( 3.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 0QSS ( 82.8% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 0QSS è previsto essere elevato tra 3 anni

PHAXIAM Therapeutics Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

No longer forecast to breakeven

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.70

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.80

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €8.07

New 90-day high: €6.55

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita